Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease

Davies, Stefan M.K.; Nguyen, Tran M; Parker, Claire E; MacDonald, John K; Jairath, Vipul; Khanna, Reena

doi:10.1002/14651858.cd012804.pub2

Cited by 16 publications

(7 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ustekinumab, an antibody against IL-21 and IL-21, also decreases IL-17 production in the lymphocytes of lamina propria, which inhibits both Th17 and Th1 cells (Fina et al, 2008;Sandborn et al, 2012). In ustekinumab clinical trials, the most common adverse reactions included nasopharyngitis, upper respiratory tract infection, and cough (Davies et al, 2019). Some drugs target the components of the transport pathway, such as MadCAM-1 targeting the adhesion molecules, and anti-α4β7, natalizumab, vedolizumab, and etrolizumab targeting anti-integrin (Moens et al, 2019;Allner et al, 2020).…”

Section: Therapeutic Targets and Drug-use Strategy For Inflammatory Bowel Diseasementioning

confidence: 99%

Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease

et al. 2021

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) represents chronic recurrent intestinal inflammation resulting from various factors. Crohn’s disease (CD) and ulcerative colitis (UC) have been identified as the two major types of IBD. Currently, most of the drugs for IBD used commonly in the clinic have adverse reactions, and only a few drugs present long-lasting treatment effects. Moreover, issues of drug resistance and disease recurrence are frequent and difficult to resolve. Together, these issues cause difficulties in treating patients with IBD. Therefore, the development of novel therapeutic agents for the prevention and treatment of IBD is of significance. In this context, research on natural compounds exhibiting anti-inflammatory activity could be a novel approach to developing effective therapeutic strategies for IBD. Phytochemicals such as astragalus polysaccharide (APS), quercetin, limonin, ginsenoside Rd, luteolin, kaempferol, and icariin are reported to be effective in IBD treatment. In brief, natural compounds with anti-inflammatory activities are considered important candidate drugs for IBD treatment. The present review discusses the potential of certain natural compounds and their synthetic derivatives in the prevention and treatment of IBD.

show abstract

Section: Therapeutic Targets and Drug-use Strategy For Inflammatory Bowel Diseasementioning

confidence: 99%

Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In conclusion, various lines of evidence have suggested that IL-23 is an effector cytokine in the innate gut immune system, which may be a more specific target for the treatment of CD. Additionally, preclinical studies have shown no benefit of selective blocking of IL-12 in IBD [ 41 , 42 ], and other studies in animal models have demonstrated that blocking IL-23 is more important than IL-12 in suppressing intestinal inflammation [ 43 - 45 ]. Research by Chapuy et al .…”

Section: Discussionmentioning

confidence: 99%

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials

Gao,

Shentu,

Sha

et al. 2023

cejoi

View full text Add to dashboard Cite

Introduction A growing number of randomized controlled trials (RCTs) have demonstrated the effectiveness of interleukin (IL)-23 and IL-12/23 inhibitors in treating Crohn’s disease (CD). This study evaluated the efficacy of IL-23 and IL-12/23 inhibitors in the induction phase for the treatment of CD. Material and methods We searched the following databases from inception until December, 2022: Medline, Embase, Web of Science and the Cochrane Library. The primary outcome was the proportion of CD patients who achieved clinical remission at the end of the induction therapy period. Secondary outcomes included clinical response, endoscopic remission, endoscopic response and normalized C-reactive protein (CRP). Results After screening, 7 RCTs were included in our study. The meta-analysis showed that, in the induction period, more patients treated with IL-23 inhibitors and IL-12/23 inhibitors achieved clinical remission than patients with placebo therapy (RR = 2.11, 95% CI: 1.83-2.44; RR = 1.94, 95% CI: 1.64-2.29; respectively). The IL-23 inhibitor group and the IL-12/23 inhibitor group showed higher clinical response rates than the placebo group (RR = 1.92, 95% CI: 1.74-2,11; RR = 1.83, 95% CI: 1.61-2.09; respectively). In addition, the IL-23 inhibitor group had a higher endoscopic remission rate and endoscopic response rate than the placebo group; the corresponding pooled RRs were 3.40 (95% CI: 2.57-4.50) and 2.65 (95% CI: 2.65-3.12), respectively. Conclusions IL-23 and IL-12/23 inhibitors were efficient methods in the induction treatment of CD.

show abstract

“…Ustekinumab, an antibody that blocks IL-12 and IL-23, has been greenlighted for the treatment of CD and UC ( 122 ). Briakinumab, another antibody that inhibits IL-23 and IL-12 in combination, is effective against IBD although it has been discontinued ( 123 ). Several anti-IL-23p19-specific antibodies have undergone or are presently undertaking clinical studies for IBD, such as brazikumab, risankizumab, mirikizumab, and guselkumab ( 124 – 127 ).…”

Section: The Therapeutic Potential Of Ibd By Targeting Th17 Cellsmentioning

confidence: 99%

The role of Th17 cells in inflammatory bowel disease and the research progress

et al. 2023

View full text Add to dashboard Cite

Th17 cells play an important role in the abnormal immune response in inflammatory bowel disease (IBD) and are involved in the development and progression of inflammation and fibrosis. An increasing amount of data has shown that gut microbes are important parts of intestinal immunity and regulators of Th17 cellular immunity. Th17 cell differentiation is regulated by intestinal bacteria and cytokines, and Th17 cells regulate the intestinal mucosal immune microenvironment by secreting cytokines, such as IL-17, IL-21, and IL-26. Solid evidence showed that, regarding the treatment of IBD by targeting Th17 cells, the therapeutic effect of different biological agents varies greatly. Fecal bacteria transplantation (FMT) in the treatment of IBD has been a popular research topic in recent years and is safe and effective with few side effects. To further understand the role of Th17 cells in the progression of IBD and associated therapeutic prospects, this review will discuss the progress of related research on Th17 cells in IBD by focusing on the interaction and immune regulation between Th17 cells and gut microbiota.

show abstract

Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease

Cited by 16 publications

References 70 publications

Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease

Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials

The role of Th17 cells in inflammatory bowel disease and the research progress

Contact Info

Product

Resources

About